• Oral Gepotidacin in Urogenital Gonorrhoea: Phase 3 Evidence

  2026-06-13

  The EAGLE-1 phase 3 trial establishes oral gepotidacin as a non-inferior alternative to standard dual therapy for uncomplicated urogenital gonorrhoea. This work advances the clinical landscape by demonstrating high microbiological cure rates and a manageable safety profile, paving the way for new oral treatment options amid rising antimicrobial resistance.

• Faropenem Sodium: Penem Antibiotic Workflows for AMR Researc

  2026-06-12

  Faropenem sodium stands out as a penem antibiotic with remarkable oral bioavailability and unmatched activity across Gram-positive, Gram-negative, and anaerobic bacteria, making it invaluable for antimicrobial resistance (AMR) research. This article provides actionable protocols, troubleshooting insights, and an evidence-based outlook to help researchers leverage Faropenem sodium for advanced infection modeling and resistance studies.

• Liproxstatin-1 HCl: Elevating Ferroptosis Research for Trans

  2026-06-12

  Explore how Liproxstatin-1 HCl advances the dissection of ferroptosis mechanisms, integrates with cutting-edge discoveries in mitochondrial calcium signaling, and provides translational researchers with a strategic foundation for modeling and modulating iron-dependent cell death in acute organ injury and cancer.

• Angiotensin III: Mechanistic Insights Empowering RAAS Resear

  2026-06-11

  Explore the evolving role of Angiotensin III in RAAS signaling, experimental modeling, and translational pipelines. This article blends mechanistic depth with actionable guidance for researchers, contextualizes recent findings on angiotensin peptides and viral pathogenesis, and positions APExBIO’s Angiotensin III (human, mouse) as a gold-standard tool for cardiovascular and neuroendocrine studies.

• Open Platform DLP Enables Precision Hydrogel Printing in 96-

  2026-06-11

  The reference study introduces a low-cost, open platform digital light printer (OP-DLP) for high-throughput, spatially controlled hydrogel fabrication in standard 96-well plates. This innovation streamlines localized light-activation and hydrogel patterning, enhancing reproducibility and flexibility for biomaterials and cell-based research.

• Sodium Picosulfate in Experimental Constipation: Protocols &

  2026-06-10

  Sodium Picosulfate empowers gut–liver–brain axis research with unmatched solubility and workflow control, enabling robust chronic and opioid-induced constipation models. Discover protocol strategies, troubleshooting tips, and translational insights from recent neuroinflammation imaging advances.

• Combined Activity of Temafloxacin Against Mycobacterium aviu

  2026-06-10

  This article examines the in vitro evaluation of temafloxacin, clarithromycin, and ethambutol—alone and in combination—against Mycobacterium avium complex (MAC) strains, as detailed in a pivotal 1993 study. Key findings highlight the additive and synergistic effects of these agents, supporting the rationale for multidrug regimens in research on intracellular mycobacterial infections.

• Methicillin Sodium Salt: Precision Tools for Resistance Mech

  2026-06-09

  Explore Methicillin sodium salt as a pivotal bacterial cell wall synthesis inhibitor for advanced resistance mechanism mapping. This article reveals how integrating high-throughput approaches with APExBIO’s C3238 empowers next-generation Staphylococcus aureus infection research.

• Levofloxacin: Applied Protocols for Resistance and Bone Rese

  2026-06-09

  Levofloxacin, a synthetic fluoroquinolone antibiotic, is uniquely positioned for both multidrug resistance studies and probing bone cell biology. Discover protocol enhancements, troubleshooting strategies, and applied insights to maximize Levofloxacin’s research potential in antimicrobial and osteoblast assays.

• Temafloxacin’s In Vitro Efficacy Against Gram-Negative Patho

  2026-06-08

  The reference study systematically evaluates temafloxacin’s in vitro antibacterial potency against a broad spectrum of Gram-negative bacteria, including key respiratory and enteric pathogens. By providing comparative MIC data versus established fluoroquinolones, the work highlights both the innovation and the practical boundaries of temafloxacin as a research tool in infection biology.

• 5-HT3 Antiemetic Drugs Inhibit Renal OCT2 and MATE1 Secretio

  2026-06-08

  This study systematically evaluates the inhibitory effects of five 5-HT3 antagonist antiemetic drugs on human renal OCT2 and MATE1 transporters using overexpression and transfected cell models. The findings highlight the potential for clinically relevant drug-drug interactions affecting the renal secretion of cationic drugs, and provide quantitative potency data for each compound.

• Intra- and Extracellular Dicloxacillin Activity Against MSSA

  2026-06-07

  This article examines the landmark study on dicloxacillin's intra- and extracellular efficacy against methicillin-sensitive Staphylococcus aureus (MSSA). The research clarifies that the minimum inhibitory concentration (MIC) is a reliable predictor of efficacy in both compartments and establishes time above MIC (fTMIC) as the most predictive PK/PD index for optimizing β-lactam antibiotic interventions.

• Cefazedone (Refosporen): Optimized Antibacterial Workflows

  2026-06-06

  Cefazedone (Refosporen) stands out as a robust first-generation cephalosporin, offering β-lactamase-resistant activity for both Gram-positive and Gram-negative infections. This article details actionable experimental workflows, troubleshooting strategies, and data-driven insights for leveraging Cefazedone in in vitro and clinical research.

• Tropifexor (LJN452): Potent FXR Agonist for Intestinal Barri

  2026-06-05

  Tropifexor (LJN452) is a highly potent synthetic FXR agonist with an EC50 of 0.2 nM. Recent studies demonstrate its efficacy in improving intestinal defense and epithelial barrier function in neonatal piglet models. APExBIO supplies Tropifexor for robust and reproducible research in metabolic and liver disease models.

• Sodium Dicloxacillin Monohydrate: Precision for Translationa

  2026-06-05

  This thought-leadership article unpacks the mechanistic, experimental, and translational value of sodium dicloxacillin monohydrate for methicillin-sensitive Staphylococcus aureus (MSSA) infection research. By integrating mechanistic insights, competitive analysis, and actionable workflow guidance, we empower translational researchers to advance the fidelity and impact of their Gram-positive bacterial infection models. The discussion contextualizes APExBIO’s product within the broader landscape of β-lactam antibiotics, leveraging both peer-reviewed and industry evidence to define best practices and identify emerging opportunities.

455 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page